Gain perspectives on strategies for optimizing use of CDK4/6 and PI3K inhibitors for HR+/HER2- breast cancer, including discussion on effective patient education about these targeted oral therapies! Learn from the experts with downloadable slides, commentaries, podcast, on-demand Webcast, and an Interactive Decision Support Tool providing personalized management recommendations for adverse events associated with CDK4/6 and PI3K inhibitors.
Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer
Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with oral targeted therapy for HR-positive, HER2-negative breast cancer from 5 experts.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.